ESCRS - POCOR253 - Long-Term Outcome Of Endothelial Keratoplasty Among Glaucoma Patients And The Risk Of Prostaglandin Analogue (Latanoprost) Use On Graft Rejection

Long-Term Outcome Of Endothelial Keratoplasty Among Glaucoma Patients And The Risk Of Prostaglandin Analogue (Latanoprost) Use On Graft Rejection

Published 2026 - 44th Congress of the ESCRS

Reference: POCOR253 | Type: Free paper | DOI: 10.82333/w7ec-mv55

Authors: Dr Munirah Aldofyan* 1 , Dr Majed Alkharashi 1 , Dr Mohammed Abusayf 1

1Ophthalmology,King Saud University,Riyadh,Saudi Arabia

Purpose

To evaluate the long-term outcomes of Descemet stripping automated endothelial keratoplasty (DSAEK) in patients with glaucoma and to investigate if the usage of the prostaglandin analog latanoprost increases the risk of graft rejection.

Setting

Single-center retrospective review conducted at King Abdulaziz University Hospital, Riyadh,

Saudi Arabia.

Methods

This study retrospectively reviewed 65 eyes of 61 patients with glaucoma who underwent DSAEK at King Abdulaziz University Hospital between 2009 and 2024. The risk factors for graft rejection were identified using Kaplan–Meier survival analysis and univariate and multivariate Cox regression models. 

Results

The graft survival rates among patients with glaucoma at 1, 3, and 5 years were 72.4%, 23.1%, and 11.5%, respectively. Latanoprost use was significantly associated with graft failure (71.4% vs. 28.6%, p = 0.024). The graft failure was mostly secondary failure (80%, p = 0.015) and was often linked to endothelial rejection episodes (62.5%). Other antiglaucoma medications were not associated with graft failure.

Conclusions

Glaucoma decreases graft longevity after DSAEK. Latanoprost use may further increase the risk of graft rejection by enhancing inflammatory or immune responses. Prospective studies are warranted to confirm these findings.